Although “new quadruple” drugs for heart failure such as ACEI/ARB/ARNI (Benazepril, Valsartan, Sacubitril/valsartan, etc.), beta blockers (Metoprolol, Bisoprolol), aldosterone receptor antagonists (Spironolactone), SGLT2 inhibitors (Engliflozin, Dagliflozin, etc.)have brought hope to the treatment of patients with heart failure (7), many patients still experience poor control every year requiring repeated hospitalization or even leading to death. The gene discussed is SLC5A2; the disease is heart failure.